CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: INFANTILE SPASMS THERAPEUTICS MARKET, BY DRUG TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Drug Type
4.2. Corticosteroids
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Adrenocorticotropic Hormones (ACTH)
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Antiepileptic Drugs (AEDs)
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
4.5. Others
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.5.2. Market Size and Forecast, By Region
4.5.3. Market Share Analysis, By Country
CHAPTER 5: INFANTILE SPASMS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
5.1. Market Overview
5.1.1 Market Size and Forecast, By Route Of Administration
5.2. Oral
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Parenteral
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
CHAPTER 6: INFANTILE SPASMS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
6.1. Market Overview
6.1.1 Market Size and Forecast, By Distribution Channel
6.2. Hospital Pharmacies
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, By Region
6.2.3. Market Share Analysis, By Country
6.3. Drug Stores And Retail Pharmacies
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, By Region
6.3.3. Market Share Analysis, By Country
6.4. Online Providers
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Size and Forecast, By Region
6.4.3. Market Share Analysis, By Country
CHAPTER 7: INFANTILE SPASMS THERAPEUTICS MARKET, BY REGION
7.1. Market Overview
7.1.1 Market Size and Forecast, By Region
7.2. North America
7.2.1. Key Market Trends and Opportunities
7.2.2. Market Size and Forecast, By Drug Type
7.2.3. Market Size and Forecast, By Route Of Administration
7.2.4. Market Size and Forecast, By Distribution Channel
7.2.5. Market Size and Forecast, By Country
7.2.6. U.S. Infantile Spasms Therapeutics Market
7.2.6.1. Market Size and Forecast, By Drug Type
7.2.6.2. Market Size and Forecast, By Route Of Administration
7.2.6.3. Market Size and Forecast, By Distribution Channel
7.2.7. Canada Infantile Spasms Therapeutics Market
7.2.7.1. Market Size and Forecast, By Drug Type
7.2.7.2. Market Size and Forecast, By Route Of Administration
7.2.7.3. Market Size and Forecast, By Distribution Channel
7.2.8. Mexico Infantile Spasms Therapeutics Market
7.2.8.1. Market Size and Forecast, By Drug Type
7.2.8.2. Market Size and Forecast, By Route Of Administration
7.2.8.3. Market Size and Forecast, By Distribution Channel
7.3. Europe
7.3.1. Key Market Trends and Opportunities
7.3.2. Market Size and Forecast, By Drug Type
7.3.3. Market Size and Forecast, By Route Of Administration
7.3.4. Market Size and Forecast, By Distribution Channel
7.3.5. Market Size and Forecast, By Country
7.3.6. France Infantile Spasms Therapeutics Market
7.3.6.1. Market Size and Forecast, By Drug Type
7.3.6.2. Market Size and Forecast, By Route Of Administration
7.3.6.3. Market Size and Forecast, By Distribution Channel
7.3.7. Germany Infantile Spasms Therapeutics Market
7.3.7.1. Market Size and Forecast, By Drug Type
7.3.7.2. Market Size and Forecast, By Route Of Administration
7.3.7.3. Market Size and Forecast, By Distribution Channel
7.3.8. Italy Infantile Spasms Therapeutics Market
7.3.8.1. Market Size and Forecast, By Drug Type
7.3.8.2. Market Size and Forecast, By Route Of Administration
7.3.8.3. Market Size and Forecast, By Distribution Channel
7.3.9. Spain Infantile Spasms Therapeutics Market
7.3.9.1. Market Size and Forecast, By Drug Type
7.3.9.2. Market Size and Forecast, By Route Of Administration
7.3.9.3. Market Size and Forecast, By Distribution Channel
7.3.10. UK Infantile Spasms Therapeutics Market
7.3.10.1. Market Size and Forecast, By Drug Type
7.3.10.2. Market Size and Forecast, By Route Of Administration
7.3.10.3. Market Size and Forecast, By Distribution Channel
7.3.11. Rest Of Europe Infantile Spasms Therapeutics Market
7.3.11.1. Market Size and Forecast, By Drug Type
7.3.11.2. Market Size and Forecast, By Route Of Administration
7.3.11.3. Market Size and Forecast, By Distribution Channel
7.4. Asia-Pacific
7.4.1. Key Market Trends and Opportunities
7.4.2. Market Size and Forecast, By Drug Type
7.4.3. Market Size and Forecast, By Route Of Administration
7.4.4. Market Size and Forecast, By Distribution Channel
7.4.5. Market Size and Forecast, By Country
7.4.6. China Infantile Spasms Therapeutics Market
7.4.6.1. Market Size and Forecast, By Drug Type
7.4.6.2. Market Size and Forecast, By Route Of Administration
7.4.6.3. Market Size and Forecast, By Distribution Channel
7.4.7. Japan Infantile Spasms Therapeutics Market
7.4.7.1. Market Size and Forecast, By Drug Type
7.4.7.2. Market Size and Forecast, By Route Of Administration
7.4.7.3. Market Size and Forecast, By Distribution Channel
7.4.8. India Infantile Spasms Therapeutics Market
7.4.8.1. Market Size and Forecast, By Drug Type
7.4.8.2. Market Size and Forecast, By Route Of Administration
7.4.8.3. Market Size and Forecast, By Distribution Channel
7.4.9. South Korea Infantile Spasms Therapeutics Market
7.4.9.1. Market Size and Forecast, By Drug Type
7.4.9.2. Market Size and Forecast, By Route Of Administration
7.4.9.3. Market Size and Forecast, By Distribution Channel
7.4.10. Australia Infantile Spasms Therapeutics Market
7.4.10.1. Market Size and Forecast, By Drug Type
7.4.10.2. Market Size and Forecast, By Route Of Administration
7.4.10.3. Market Size and Forecast, By Distribution Channel
7.4.11. Rest of Asia-Pacific Infantile Spasms Therapeutics Market
7.4.11.1. Market Size and Forecast, By Drug Type
7.4.11.2. Market Size and Forecast, By Route Of Administration
7.4.11.3. Market Size and Forecast, By Distribution Channel
7.5. LAMEA
7.5.1. Key Market Trends and Opportunities
7.5.2. Market Size and Forecast, By Drug Type
7.5.3. Market Size and Forecast, By Route Of Administration
7.5.4. Market Size and Forecast, By Distribution Channel
7.5.5. Market Size and Forecast, By Country
7.5.6. Brazil Infantile Spasms Therapeutics Market
7.5.6.1. Market Size and Forecast, By Drug Type
7.5.6.2. Market Size and Forecast, By Route Of Administration
7.5.6.3. Market Size and Forecast, By Distribution Channel
7.5.7. South Africa Infantile Spasms Therapeutics Market
7.5.7.1. Market Size and Forecast, By Drug Type
7.5.7.2. Market Size and Forecast, By Route Of Administration
7.5.7.3. Market Size and Forecast, By Distribution Channel
7.5.8. Saudi Arabia Infantile Spasms Therapeutics Market
7.5.8.1. Market Size and Forecast, By Drug Type
7.5.8.2. Market Size and Forecast, By Route Of Administration
7.5.8.3. Market Size and Forecast, By Distribution Channel
7.5.9. Rest of LAMEA Infantile Spasms Therapeutics Market
7.5.9.1. Market Size and Forecast, By Drug Type
7.5.9.2. Market Size and Forecast, By Route Of Administration
7.5.9.3. Market Size and Forecast, By Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping Of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning, 2023
CHAPTER 9: COMPANY PROFILES
9.1. Mallinckrodt Pharmaceuticals
9.1.1. Company Overview
9.1.2. Key Executives
9.1.3. Company Snapshot
9.1.4. Operating Business Segments
9.1.5. Product Portfolio
9.1.6. Business Performance
9.1.7. Key Strategic Moves and Developments
9.2. H. Lundbeck A/S
9.2.1. Company Overview
9.2.2. Key Executives
9.2.3. Company Snapshot
9.2.4. Operating Business Segments
9.2.5. Product Portfolio
9.2.6. Business Performance
9.2.7. Key Strategic Moves and Developments
9.3. Pfizer Inc.
9.3.1. Company Overview
9.3.2. Key Executives
9.3.3. Company Snapshot
9.3.4. Operating Business Segments
9.3.5. Product Portfolio
9.3.6. Business Performance
9.3.7. Key Strategic Moves and Developments
9.4. UCB Pharma S.A.
9.4.1. Company Overview
9.4.2. Key Executives
9.4.3. Company Snapshot
9.4.4. Operating Business Segments
9.4.5. Product Portfolio
9.4.6. Business Performance
9.4.7. Key Strategic Moves and Developments
9.5. Jazz Pharmaceuticals, Inc.
9.5.1. Company Overview
9.5.2. Key Executives
9.5.3. Company Snapshot
9.5.4. Operating Business Segments
9.5.5. Product Portfolio
9.5.6. Business Performance
9.5.7. Key Strategic Moves and Developments
9.6. Novartis AG
9.6.1. Company Overview
9.6.2. Key Executives
9.6.3. Company Snapshot
9.6.4. Operating Business Segments
9.6.5. Product Portfolio
9.6.6. Business Performance
9.6.7. Key Strategic Moves and Developments
9.7. Teva Pharmaceutical Industries Ltd.
9.7.1. Company Overview
9.7.2. Key Executives
9.7.3. Company Snapshot
9.7.4. Operating Business Segments
9.7.5. Product Portfolio
9.7.6. Business Performance
9.7.7. Key Strategic Moves and Developments
9.8. Sun Pharmaceutical Industries Ltd.
9.8.1. Company Overview
9.8.2. Key Executives
9.8.3. Company Snapshot
9.8.4. Operating Business Segments
9.8.5. Product Portfolio
9.8.6. Business Performance
9.8.7. Key Strategic Moves and Developments
9.9. Viatris Inc.
9.9.1. Company Overview
9.9.2. Key Executives
9.9.3. Company Snapshot
9.9.4. Operating Business Segments
9.9.5. Product Portfolio
9.9.6. Business Performance
9.9.7. Key Strategic Moves and Developments
9.10. AbbVie Inc.
9.10.1. Company Overview
9.10.2. Key Executives
9.10.3. Company Snapshot
9.10.4. Operating Business Segments
9.10.5. Product Portfolio
9.10.6. Business Performance
9.10.7. Key Strategic Moves and Developments
LIST OF TABLES
Table 1. Global Infantile Spasms Therapeutics Market, by Drug Type, 2024 - 2033 ($Million)
Table 2. Infantile Spasms Therapeutics Market for Corticosteroids, by Region, 2024 - 2033 ($Million)
Table 3. Infantile Spasms Therapeutics Market for Adrenocorticotropic Hormones (Acth), by Region, 2024 - 2033 ($Million)
Table 4. Infantile Spasms Therapeutics Market for Antiepileptic Drugs (Aeds), by Region, 2024 - 2033 ($Million)
Table 5. Infantile Spasms Therapeutics Market for Others, by Region, 2024 - 2033 ($Million)
Table 6. Global Infantile Spasms Therapeutics Market, by Route of Administration, 2024 - 2033 ($Million)
Table 7. Infantile Spasms Therapeutics Market for Oral, by Region, 2024 - 2033 ($Million)
Table 8. Infantile Spasms Therapeutics Market for Parenteral, by Region, 2024 - 2033 ($Million)
Table 9. Global Infantile Spasms Therapeutics Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 10. Infantile Spasms Therapeutics Market for Hospital Pharmacies, by Region, 2024 - 2033 ($Million)
Table 11. Infantile Spasms Therapeutics Market for Drug Stores and Retail Pharmacies, by Region, 2024 - 2033 ($Million)
Table 12. Infantile Spasms Therapeutics Market for Online Providers, by Region, 2024 - 2033 ($Million)
Table 13. Infantile Spasms Therapeutics Market, by Region, 2024 - 2033 ($Million)
Table 14. North America Infantile Spasms Therapeutics Market, by Country, 2024 - 2033 ($Million)
Table 15. North America Infantile Spasms Therapeutics Market, by Drug Type, 2024 - 2033 ($Million)
Table 16. North America Infantile Spasms Therapeutics Market, by Route of Administration, 2024 - 2033 ($Million)
Table 17. North America Infantile Spasms Therapeutics Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 18. U.S. Infantile Spasms Therapeutics Market, by Drug Type, 2024 - 2033 ($Million)
Table 19. U.S. Infantile Spasms Therapeutics Market, by Route of Administration, 2024 - 2033 ($Million)
Table 20. U.S. Infantile Spasms Therapeutics Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 21. Canada Infantile Spasms Therapeutics Market, by Drug Type, 2024 - 2033 ($Million)
Table 22. Canada Infantile Spasms Therapeutics Market, by Route of Administration, 2024 - 2033 ($Million)
Table 23. Canada Infantile Spasms Therapeutics Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 24. Mexico Infantile Spasms Therapeutics Market, by Drug Type, 2024 - 2033 ($Million)
Table 25. Mexico Infantile Spasms Therapeutics Market, by Route of Administration, 2024 - 2033 ($Million)
Table 26. Mexico Infantile Spasms Therapeutics Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 27. Europe Infantile Spasms Therapeutics Market, by Country, 2024 - 2033 ($Million)
Table 28. Europe Infantile Spasms Therapeutics Market, by Drug Type, 2024 - 2033 ($Million)
Table 29. Europe Infantile Spasms Therapeutics Market, by Route of Administration, 2024 - 2033 ($Million)
Table 30. Europe Infantile Spasms Therapeutics Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 31. France Infantile Spasms Therapeutics Market, by Drug Type, 2024 - 2033 ($Million)
Table 32. France Infantile Spasms Therapeutics Market, by Route of Administration, 2024 - 2033 ($Million)
Table 33. France Infantile Spasms Therapeutics Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 34. Germany Infantile Spasms Therapeutics Market, by Drug Type, 2024 - 2033 ($Million)
Table 35. Germany Infantile Spasms Therapeutics Market, by Route of Administration, 2024 - 2033 ($Million)
Table 36. Germany Infantile Spasms Therapeutics Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 37. Italy Infantile Spasms Therapeutics Market, by Drug Type, 2024 - 2033 ($Million)
Table 38. Italy Infantile Spasms Therapeutics Market, by Route of Administration, 2024 - 2033 ($Million)
Table 39. Italy Infantile Spasms Therapeutics Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 40. Spain Infantile Spasms Therapeutics Market, by Drug Type, 2024 - 2033 ($Million)
Table 41. Spain Infantile Spasms Therapeutics Market, by Route of Administration, 2024 - 2033 ($Million)
Table 42. Spain Infantile Spasms Therapeutics Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 43. UK Infantile Spasms Therapeutics Market, by Drug Type, 2024 - 2033 ($Million)
Table 44. UK Infantile Spasms Therapeutics Market, by Route of Administration, 2024 - 2033 ($Million)
Table 45. UK Infantile Spasms Therapeutics Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 46. Rest of Europe Infantile Spasms Therapeutics Market, by Drug Type, 2024 - 2033 ($Million)
Table 47. Rest of Europe Infantile Spasms Therapeutics Market, by Route of Administration, 2024 - 2033 ($Million)
Table 48. Rest of Europe Infantile Spasms Therapeutics Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 49. Asia-Pacific Infantile Spasms Therapeutics Market, by Country, 2024 - 2033 ($Million)
Table 50. Asia-Pacific Infantile Spasms Therapeutics Market, by Drug Type, 2024 - 2033 ($Million)
Table 51. Asia-Pacific Infantile Spasms Therapeutics Market, by Route of Administration, 2024 - 2033 ($Million)
Table 52. Asia-Pacific Infantile Spasms Therapeutics Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 53. China Infantile Spasms Therapeutics Market, by Drug Type, 2024 - 2033 ($Million)
Table 54. China Infantile Spasms Therapeutics Market, by Route of Administration, 2024 - 2033 ($Million)
Table 55. China Infantile Spasms Therapeutics Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 56. Japan Infantile Spasms Therapeutics Market, by Drug Type, 2024 - 2033 ($Million)
Table 57. Japan Infantile Spasms Therapeutics Market, by Route of Administration, 2024 - 2033 ($Million)
Table 58. Japan Infantile Spasms Therapeutics Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 59. India Infantile Spasms Therapeutics Market, by Drug Type, 2024 - 2033 ($Million)
Table 60. India Infantile Spasms Therapeutics Market, by Route of Administration, 2024 - 2033 ($Million)
Table 61. India Infantile Spasms Therapeutics Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 62. South Korea Infantile Spasms Therapeutics Market, by Drug Type, 2024 - 2033 ($Million)
Table 63. South Korea Infantile Spasms Therapeutics Market, by Route of Administration, 2024 - 2033 ($Million)
Table 64. South Korea Infantile Spasms Therapeutics Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 65. Australia Infantile Spasms Therapeutics Market, by Drug Type, 2024 - 2033 ($Million)
Table 66. Australia Infantile Spasms Therapeutics Market, by Route of Administration, 2024 - 2033 ($Million)
Table 67. Australia Infantile Spasms Therapeutics Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 68. Rest of Asia-Pacific Infantile Spasms Therapeutics Market, by Drug Type, 2024 - 2033 ($Million)
Table 69. Rest of Asia-Pacific Infantile Spasms Therapeutics Market, by Route of Administration, 2024 - 2033 ($Million)
Table 70. Rest of Asia-Pacific Infantile Spasms Therapeutics Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 71. LAMEA Infantile Spasms Therapeutics Market, by Country, 2024 - 2033 ($Million)
Table 72. LAMEA Infantile Spasms Therapeutics Market, by Drug Type, 2024 - 2033 ($Million)
Table 73. LAMEA Infantile Spasms Therapeutics Market, by Route of Administration, 2024 - 2033 ($Million)
Table 74. LAMEA Infantile Spasms Therapeutics Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 75. Brazil Infantile Spasms Therapeutics Market, by Drug Type, 2024 - 2033 ($Million)
Table 76. Brazil Infantile Spasms Therapeutics Market, by Route of Administration, 2024 - 2033 ($Million)
Table 77. Brazil Infantile Spasms Therapeutics Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 78. South Africa Infantile Spasms Therapeutics Market, by Drug Type, 2024 - 2033 ($Million)
Table 79. South Africa Infantile Spasms Therapeutics Market, by Route of Administration, 2024 - 2033 ($Million)
Table 80. South Africa Infantile Spasms Therapeutics Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 81. Saudi Arabia Infantile Spasms Therapeutics Market, by Drug Type, 2024 - 2033 ($Million)
Table 82. Saudi Arabia Infantile Spasms Therapeutics Market, by Route of Administration, 2024 - 2033 ($Million)
Table 83. Saudi Arabia Infantile Spasms Therapeutics Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 84. Rest of LAMEA Infantile Spasms Therapeutics Market, by Drug Type, 2024 - 2033 ($Million)
Table 85. Rest of LAMEA Infantile Spasms Therapeutics Market, by Route of Administration, 2024 - 2033 ($Million)
Table 86. Rest of LAMEA Infantile Spasms Therapeutics Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 87. Mallinckrodt Pharmaceuticals: Key Executives
Table 88. Mallinckrodt Pharmaceuticals: Company Snapshot
Table 89. Mallinckrodt Pharmaceuticals: Operating Segments
Table 90. Mallinckrodt Pharmaceuticals: Product Portfolio
Table 91. Mallinckrodt Pharmaceuticals: Key Strategic Moves and Developments
Table 92. H. Lundbeck A/S: Key Executives
Table 93. H. Lundbeck A/S: Company Snapshot
Table 94. H. Lundbeck A/S: Operating Segments
Table 95. H. Lundbeck A/S: Product Portfolio
Table 96. H. Lundbeck A/S: Key Strategic Moves and Developments
Table 97. Pfizer Inc.: Key Executives
Table 98. Pfizer Inc.: Company Snapshot
Table 99. Pfizer Inc.: Operating Segments
Table 100. Pfizer Inc.: Product Portfolio
Table 101. Pfizer Inc.: Key Strategic Moves and Developments
Table 102. Ucb Pharma SA: Key Executives
Table 103. Ucb Pharma SA: Company Snapshot
Table 104. Ucb Pharma SA: Operating Segments
Table 105. Ucb Pharma SA: Product Portfolio
Table 106. Ucb Pharma SA: Key Strategic Moves and Developments
Table 107. Jazz Pharmaceuticals, Inc.: Key Executives
Table 108. Jazz Pharmaceuticals, Inc.: Company Snapshot
Table 109. Jazz Pharmaceuticals, Inc.: Operating Segments
Table 110. Jazz Pharmaceuticals, Inc.: Product Portfolio
Table 111. Jazz Pharmaceuticals, Inc.: Key Strategic Moves and Developments
Table 112. Novartis AG: Key Executives
Table 113. Novartis AG: Company Snapshot
Table 114. Novartis AG: Operating Segments
Table 115. Novartis AG: Product Portfolio
Table 116. Novartis AG: Key Strategic Moves and Developments
Table 117. Teva Pharmaceutical Industries Ltd.: Key Executives
Table 118. Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 119. Teva Pharmaceutical Industries Ltd.: Operating Segments
Table 120. Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 121. Teva Pharmaceutical Industries Ltd.: Key Strategic Moves and Developments
Table 122. Sun Pharmaceutical Industries Ltd.: Key Executives
Table 123. Sun Pharmaceutical Industries Ltd.: Company Snapshot
Table 124. Sun Pharmaceutical Industries Ltd.: Operating Segments
Table 125. Sun Pharmaceutical Industries Ltd.: Product Portfolio
Table 126. Sun Pharmaceutical Industries Ltd.: Key Strategic Moves and Developments
Table 127. Viatris Inc.: Key Executives
Table 128. Viatris Inc.: Company Snapshot
Table 129. Viatris Inc.: Operating Segments
Table 130. Viatris Inc.: Product Portfolio
Table 131. Viatris Inc.: Key Strategic Moves and Developments
Table 132. Abbvie Inc.: Key Executives
Table 133. Abbvie Inc.: Company Snapshot
Table 134. Abbvie Inc.: Operating Segments
Table 135. Abbvie Inc.: Product Portfolio
Table 136. Abbvie Inc.: Key Strategic Moves and Developments
LIST OF FIGURES
Figure 1. Global Infantile Spasms Therapeutics Market, 2024 - 2033
Figure 2. Segmentation of Infantile Spasms Therapeutics Market, 2024 - 2033
Figure 3. Top Investment Pocket in Infantile Spasms Therapeutics Market
Figure 4. Moderate Bargaining Power of Buyers
Figure 5. Moderate Bargaining Power of Suppliers
Figure 6. Moderate Threat of New Entrants
Figure 7. Low Threat of Substitution
Figure 8. High Competitive Rivalry
Figure 9. Opportunities, Restraints and Drivers: Globalinfantile Spasms Therapeutics Market
Figure 10. Global Infantile Spasms Therapeutics Market Segmentation, by Drug Type
Figure 11. Infantile Spasms Therapeutics Market for Corticosteroids, by Country, 2024 - 2033 ($Million)
Figure 12. Infantile Spasms Therapeutics Market for Adrenocorticotropic Hormones (Acth), by Country, 2024 - 2033 ($Million)
Figure 13. Infantile Spasms Therapeutics Market for Antiepileptic Drugs (Aeds), by Country, 2024 - 2033 ($Million)
Figure 14. Infantile Spasms Therapeutics Market for Others, by Country, 2024 - 2033 ($Million)
Figure 15. Global Infantile Spasms Therapeutics Market Segmentation, by Route of Administration
Figure 16. Infantile Spasms Therapeutics Market for Oral, by Country, 2024 - 2033 ($Million)
Figure 17. Infantile Spasms Therapeutics Market for Parenteral, by Country, 2024 - 2033 ($Million)
Figure 18. Global Infantile Spasms Therapeutics Market Segmentation, by Distribution Channel
Figure 19. Infantile Spasms Therapeutics Market for Hospital Pharmacies, by Country, 2024 - 2033 ($Million)
Figure 20. Infantile Spasms Therapeutics Market for Drug Stores and Retail Pharmacies, by Country, 2024 - 2033 ($Million)
Figure 21. Infantile Spasms Therapeutics Market for Online Providers, by Country, 2024 - 2033 ($Million)
Figure 22. Top Winning Strategies, by Year, 2021-2023*
Figure 23. Top Winning Strategies, by Development, 2021-2023*
Figure 24. Top Winning Strategies, by Company, 2021-2023*
Figure 25. Product Mapping of Top 10 Players
Figure 26. Competitive Dashboard
Figure 27. Competitive Heatmap: Infantile Spasms Therapeutics Market
Figure 28. Top Player Positioning, 2023
Figure 29. Mallinckrodt Pharmaceuticals: Net Sales, 2021-2023 ($Million)
Figure 30. Mallinckrodt Pharmaceuticals: Revenue Share, by Segment, 2023 (%)
Figure 31. Mallinckrodt Pharmaceuticals: Revenue Share, by Region, 2023 (%)
Figure 32. H. Lundbeck A/S: Net Sales, 2021-2023 ($Million)
Figure 33. H. Lundbeck A/S: Revenue Share, by Segment, 2023 (%)
Figure 34. H. Lundbeck A/S: Revenue Share, by Region, 2023 (%)
Figure 35. Pfizer Inc.: Net Sales, 2021-2023 ($Million)
Figure 36. Pfizer Inc.: Revenue Share, by Segment, 2023 (%)
Figure 37. Pfizer Inc.: Revenue Share, by Region, 2023 (%)
Figure 38. Ucb Pharma SA: Net Sales, 2021-2023 ($Million)
Figure 39. Ucb Pharma SA: Revenue Share, by Segment, 2023 (%)
Figure 40. Ucb Pharma SA: Revenue Share, by Region, 2023 (%)
Figure 41. Jazz Pharmaceuticals, Inc.: Net Sales, 2021-2023 ($Million)
Figure 42. Jazz Pharmaceuticals, Inc.: Revenue Share, by Segment, 2023 (%)
Figure 43. Jazz Pharmaceuticals, Inc.: Revenue Share, by Region, 2023 (%)
Figure 44. Novartis AG: Net Sales, 2021-2023 ($Million)
Figure 45. Novartis AG: Revenue Share, by Segment, 2023 (%)
Figure 46. Novartis AG: Revenue Share, by Region, 2023 (%)
Figure 47. Teva Pharmaceutical Industries Ltd.: Net Sales, 2021-2023 ($Million)
Figure 48. Teva Pharmaceutical Industries Ltd.: Revenue Share, by Segment, 2023 (%)
Figure 49. Teva Pharmaceutical Industries Ltd.: Revenue Share, by Region, 2023 (%)
Figure 50. Sun Pharmaceutical Industries Ltd.: Net Sales, 2021-2023 ($Million)
Figure 51. Sun Pharmaceutical Industries Ltd.: Revenue Share, by Segment, 2023 (%)
Figure 52. Sun Pharmaceutical Industries Ltd.: Revenue Share, by Region, 2023 (%)
Figure 53. Viatris Inc.: Net Sales, 2021-2023 ($Million)
Figure 54. Viatris Inc.: Revenue Share, by Segment, 2023 (%)
Figure 55. Viatris Inc.: Revenue Share, by Region, 2023 (%)
Figure 56. Abbvie Inc.: Net Sales, 2021-2023 ($Million)
Figure 57. Abbvie Inc.: Revenue Share, by Segment, 2023 (%)
Figure 58. Abbvie Inc.: Revenue Share, by Region, 2023 (%)
